(NASDAQ:FDMT), historical trading data shows that trading volumes averaged 0.66 million over the past 10 days and 579.62K over the past 3 months. If we refocus on 4D Molecular Therapeutics Inc. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are up 0.62% and 0.50% respectively in the last trading. (PFE) is also up 0.51% in trading on the day while keeping a a downtrend of -27.56% over the past year. However, the stock is -39.87% off its price a year ago. Looking at another peer, we see that Rogers Corporation (ROG) price has gained 1.44% on the day. Data shows FDMT’s intraday price has changed 6.84% in last session and 150.26% over the past year. (FDMT) and its peers suggest the former has performed considerably stronger. In the market, a comparison of 4D Molecular Therapeutics Inc. On the other hand, the stock is on average a Hold as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category. Turning to the stock’s technical picture we see that short term indicators suggest on average that FDMT is a 50% Buy. Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). The average forecast suggests up to a 492.60% growth in sales growth compared to quarterly growth in the same period last fiscal year. Per the data, EPS growth is expected to be 4.20% for 2023 and -6.30% for the next financial year. Analysts project the company’s earnings per share (EPS) to be -$0.79, which has seen fiscal year 2023 EPS growth forecast to increase to -$3.18 and about -$3.38 for fiscal year 2024.
#4D MOLECULAR THERAPEUTICS PHONE FREE#
Best of all, this upstart technology firm is currently trading undiscovered - below 25-cents per share - so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.Īll the details are in the FREE online report you can get here.ĤD Molecular Therapeutics Inc.’s market cap currently stands at around $792.90 million. One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. The result is a customized, novel, and proprietary pharmaceutical-grade product uniquely designed for targeted therapeutic gene delivery and efficacy in humans.25-cent Stock Takes $11T Commodities Sector Digital After defining the Target Product Profile, and the associated Target Vector Profile, 4DMT then applies proprietary methods to identify lead vectors from within our AAV libraries. The company’s Therapeutic Vector Evolution platform deploys over 100 million unique AAV variants from over 35 unique and proprietary 4DMT AAV libraries with extensive diversity.
Led by David Kirn, chairman and chief executive officer, 4DMT focuses on the discovery and development of targeted, customized and proprietary next-generation AAV gene therapy products for use in patients with severe genetic diseases with high unmet medical need. Its lead intravitreally-delivered AAV gene therapy asset for choroideremia is expected to enter clinical trials in 2019. The company intends to use the proceeds to advance its proprietary Therapeutic Vector Evolution platform and pipeline of next-generation AAV gene therapeutics. In conjunction with the financing, Tony Yao of ArrowMark Partners has joined the 4DMT Board of Directors. The round was led by Viking Global Investors, with participation from ArrowMark Partners, Janus Henderson Investors, The Biotechnology Value Fund, MiraeAsset Financial Group, Pappas Capital & Chiesi Ventures, Pfizer Ventures, Perceptive Advisors, Ridgeback Capital Investments, CureDuchenne Ventures and Berkeley Catalyst Fund.
#4D MOLECULAR THERAPEUTICS PHONE SERIES#
4D Molecular Therapeutics, an Emeryville, Calif.-based gene therapy company, closed a $90m Series B financing.
0 kommentar(er)
